SCHEMBL28003155

SCHEMBL28003155

COc1csc(-c2ccc(OC(F)(F)F)cc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 1/20 0.49
SHMT2 P34897 1/20 0.47
PIM1 P11309 2/20 0.46
MAPT P10636 2/20 0.46
KDM4E B2RXH2 4/20 0.44
ALDH1A1 P00352 3/20 0.44
RAB9A P51151 2/20 0.44
POLB P06746 1/20 0.44
ATM Q13315 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
F2RL3 Q96RI0 1/20 0.43
CYP19A1 P11511 2/20 0.42
CDC25A P30304 1/20 0.42
CDC25B P30305 1/20 0.42
HPGD P15428 1/20 0.42
ALPI P09923 1/20 0.41
CHRNA7 P36544 1/20 0.41
NPC1 O15118 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ALOX5 P09917 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9264337 0.81 SCN10A (0.54) SCN10ASHMT2PIM1MAPTKDM4E
SCHEMBL23367875 0.79 SHMT2 (0.50) SCN10ASHMT2PIM1MAPTALPI
SCHEMBL2090191 0.78 SHMT2 (0.56) SCN10ASHMT2PIM1MAPTKDM4E
SCHEMBL2090189 0.78 PIM1 (0.55) SCN10ASHMT2PIM1MAPTKDM4E
SCHEMBL9264332 0.78 SHMT2 (0.49) SCN10ASHMT2PIM1MAPTALPI
SCHEMBL23367910 0.78 SCN10A (0.48) SCN10ASHMT2PIM1MAPTKDM4E
SCHEMBL28817509 0.76 GFER (0.53) MAPTKDM4EALDH1A1RAB9APOLB
SCHEMBL5396498 0.75 RAB9A (0.50) MAPTKDM4EALDH1A1RAB9APOLB
SCHEMBL2088997 0.75 SHMT2 (0.61) SCN10ASHMT2PIM1MAPTKDM4E
SCHEMBL4777890 0.75 SHMT2 (0.58) SCN10ASHMT2PIM1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104583218-A Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation BRISTOL MYERS SQUIBB CO 2015-04-29 CN disclosed